Septerna, Inc. (SEPN) stock
SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30165% above fair value
$39.45−0.57 (-1.42%)
Close on Nov 18, 2026Market cap $1.84BP/E –Yield –
Septerna operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Septerna's operating income for the twelve months ending Sep 30, 2026 was -$73.39M. For fiscal 2025 it was -$68.30M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.30M | – |
| FY2024 | Dec 31, 2024 | -$80.82M | -3995.1% |
| FY2023 | Dec 31, 2023 | $2.08M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$27.23M | -1141.7% |
| Q2 FY2026 | Jun 30, 2026 | -$16.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.02M | – |
| Q3 FY2025 | Sep 30, 2025 | $2.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.72M | -172.0% |
| Q3 FY2024 | Sep 30, 2024 | -$22.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$18.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.49M | – |
| Q4 FY2023 | Dec 31, 2023 | $34.32M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.04M | – |
See a number that looks wrong?